FDA/M-CERSI Co-Processed API Workshop Proceedings.
暂无分享,去创建一个
S. Hoag | J. M. Merritt | D. Erdemir | S. Ferguson | I. Marziano | Haitao Zhang | Ramesh Sood | R. Madurawe | Sau Lee | Paresma R. Patel | Luke Schenck | L. Graham | L. Bonaga | Raimundo Ho | T. Watson | O. Dirat | B. Kline | Sharon Page | E. Hunde | C. Gazziola | Peter Capella | Steven Ferguson | Lindsey Saunders Gorka | J. Polli | M. Ramanadham | Mohan K. Sapru | Ben Stevens | Paresma Patel
[1] A. Florence,et al. A Unified AI Framework for Solubility Prediction Across Organic Solvents , 2023, Digital Discovery.
[2] J. Rowe,et al. Densifying Co-Precipitated Amorphous Dispersions to Achieve Improved Bulk Powder Properties. , 2022, Pharmaceutical research.
[3] Cameron J. Brown,et al. Comparative Studies of Powder Flow Predictions Using Milligrams of Powder for Identifying Powder Flow Issues. , 2022, International journal of pharmaceutics.
[4] J. Rowe,et al. High bulk-density amorphous dispersions to enable direct compression of reduced tablet size amorphous dosage units. , 2022, Journal of Pharmacy and Science.
[5] A. Sheikh,et al. Origins and Implications of Extraordinarily Soft Crystals in a Fixed-Dose Combination Hepatitis C Regimen , 2022, Crystal Growth & Design.
[6] S. Ferguson,et al. Integrated Purification and Formulation of an Active Pharmaceutical Ingredient via Agitated Bed Crystallization and Fluidized Bed Processing , 2022, Pharmaceutics.
[7] Luke Schenck,et al. Coprecipitated Amorphous Dispersions as Drug Substance: Opportunities and Challenges , 2021, Organic Process Research & Development.
[8] Ahmad Y. Sheikh,et al. Distinct Hybrid Hydrates of Paritaprevir: Combined Experimental and Computational Assessment of their Hydration–Dehydration Behavior and Implications for Regulatory Controls , 2021, Crystal Growth & Design.
[9] Yongchao Su,et al. Optimizing Solvent Selection and Processing Conditions to Generate High Bulk-Density, Co-Precipitated Amorphous Dispersions of Posaconazole , 2021, Pharmaceutics.
[10] Ahmad Y. Sheikh,et al. Implications of the Conformationally Flexible, Macrocyclic Structure of the First-Generation, Direct-Acting Anti-Viral Paritaprevir on Its Solid Form Complexity and Chameleonic Behavior. , 2021, Journal of the American Chemical Society.
[11] J. Beierle,et al. The Future of CMC Regulatory Submissions: Streamlining Activities Using Structured Content and Data Management. , 2021, Journal of pharmaceutical sciences.
[12] P. McArdle,et al. Factors Controlling Persistent Needle Crystal Growth: The Importance of Dominant One-Dimensional Secondary Bonding, Stacked Structures, and van der Waals Contact , 2021, Crystal growth & design.
[13] S. Ferguson,et al. Formulation of ionic liquid APIs via spray drying processes to enable conversion into single and two-phase solid forms. , 2021, International journal of pharmaceutics.
[14] Alessandra Mattei,et al. Novel Physics-Based Ensemble Modeling Approach That Utilizes 3D Molecular Conformation and Packing to Access Aqueous Thermodynamic Solubility: A Case Study of Orally Available Bromodomain and Extraterminal Domain Inhibitor Lead Optimization Series , 2021, J. Chem. Inf. Model..
[15] Christopher J Testa,et al. Heterogeneous Crystallization as a Process Intensification Technology in an Integrated Continuous Manufacturing Process for Pharmaceuticals , 2021, Organic Process Research & Development.
[16] D. Croker,et al. Manipulating Cocrystal Size and Morphology using a Combination of Temperature Cycling and Additives , 2020 .
[17] Jianhong Yang,et al. Prediction of the physical stability of amorphous solid dispersions: relationship of aging and phase separation with the thermodynamic and kinetic models along with characterization techniques , 2020, Expert Opinion on Drug Delivery.
[18] M. Capece,et al. Improving the effectiveness of the Comil as a dry-coating process: Enabling direct compaction for high drug loading formulations , 2020 .
[19] S. Ferguson,et al. Spray Encapsulation as a Formulation Strategy for Drug-Based Room Temperature Ionic Liquids: Exploiting Drug-Polymer Immiscibility to Enable Processing for Solid Dosage Forms. , 2020, Molecular pharmaceutics.
[20] D. Mcginnity,et al. Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective. , 2020, Drug discovery today.
[21] Luke Schenck,et al. Recent Advances in Co-Processed APIs and Proposals for Enabling Commercialization of These Transformative Technologies. , 2020, Molecular pharmaceutics.
[22] P. McArdle,et al. Unprecedented morphology control of gas phase cocrystal growth using multi zone heating and tailor made additives. , 2020, Chemical communications.
[23] Asher Mullard,et al. 2019 FDA drug approvals , 2020, Nature Reviews Drug Discovery.
[24] Ahmad Y. Sheikh,et al. Process development of ABT-450 – A first generation NS3/4A protease inhibitor for HCV , 2019, Tetrahedron.
[25] Bin Yang,et al. Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: Recent progress and future challenges. , 2019, Bioorganic & medicinal chemistry letters.
[26] Blair F. Johnston,et al. A random forest model for predicting crystal packing of olanzapine solvates , 2018 .
[27] N. Meanwell,et al. The expanding role of prodrugs in contemporary drug design and development , 2018, Nature Reviews Drug Discovery.
[28] M. Wendt,et al. Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection. , 2017, Journal of medicinal chemistry.
[29] Christopher J. Testa,et al. Continuous Heterogeneous Crystallization on Excipient Surfaces , 2017 .
[30] S. Vajda,et al. Quantifying the chameleonic properties of macrocycles and other high-molecular-weight drugs. , 2016, Drug discovery today.
[31] Carl J. Tilbury,et al. Predicting the Effect of Solvent on the Crystal Habit of Small Organic Molecules , 2016 .
[32] Bradley C Doak,et al. How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets. , 2016, Journal of medicinal chemistry.
[33] Erik Schultes,et al. The FAIR Guiding Principles for scientific data management and stewardship , 2016, Scientific Data.
[34] K. Sirkar,et al. Continuous preparation of polymer coated drug crystals by solid hollow fiber membrane-based cooling crystallization. , 2016, International journal of pharmaceutics.
[35] M. Capece,et al. Prediction of powder flow performance using a multi-component granular Bond number , 2015 .
[36] Blair F. Johnston,et al. A random forest model for predicting the crystallisability of organic molecules , 2015 .
[37] K. Sirkar,et al. Continuous Polymer Coating/Encapsulation of Submicrometer Particles Using a Solid Hollow Fiber Cooling Crystallization Method , 2014 .
[38] T. Blundell,et al. Structural biology and drug discovery of difficult targets: the limits of ligandability. , 2012, Chemistry & biology.
[39] Changquan Calvin Sun,et al. Profoundly improving flow properties of a cohesive cellulose powder by surface coating with nano-silica through comilling. , 2011, Journal of pharmaceutical sciences.
[40] Rajesh N. Dave,et al. Dry particle coating for improving the flowability of cohesive powders , 2005 .
[41] Kamalesh K. Sirkar,et al. Solid Hollow Fiber Cooling Crystallization , 2004 .